MedTrace Logo

A Comparison of OASIS Wound Matrix With Approved Dressings for Skin Graft Donor Sites

NCT02994589 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2016-12-16

No results posted yet for this study

Summary

The investigators objective is to compare OASIS wound matrix with other commonly used dressings available for the donor site in split thickness skin grafting in order to determine which dressing provides the best outcome based on pain level, time to healing and aesthetic outcome.

Conditions

  • Skin Graft Complications

Interventions

OTHER

Tegaderm™(Absorbant, 3M)

3M™ Tegaderm™ Dressing helps provide the natural moisture balance conducive to wound healing.

DEVICE

OASIS® wound matrix

OASIS® Matrix is indicated for the management of wounds including: partial- and full-thickness wounds, pressure ulcers, venous ulcers, chronic vascular ulcers, diabetic ulcers, trauma wounds (abrasions, lacerations, second-degree burns, skin tears), draining wounds, surgical wounds (donor sites/grafts, post-Mohs' surgery, post-laser surgery, podiatric, wound dehiscence).

OTHER

Xeroform™

Xeroform™ consists of a fine-mesh gauze impregnated with bismuth tribromophenate.

Sponsors & Collaborators

  • Loma Linda University

    lead OTHER

Principal Investigators

  • Subhas Gupta, MD, PhD · Loma Linda University

  • Hahns Kim, MD · Loma Linda University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2016-12-31
Completion
2016-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02994589 on ClinicalTrials.gov